Estrella Immunopharma (ESLA) EBT (2021 - 2026)

Estrella Immunopharma (ESLA) has reported EBT for 6 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 58.4% year-over-year to -$2.3 million in Q2 2026; TTM through Jun 2026 was -$10.0 million, a 49.61% increase from a year earlier, with the FY2025 full-year figure at -$13.1 million, down 47.67% from the prior year.
• EBT was -$2.3 million for Q2 2026 at Estrella Immunopharma, down from -$2.3 million in the prior quarter.
• Over five years, EBT peaked at -$98787.0 in Q2 2023 and troughed at -$8.4 million in Q1 2023.
• A 5-year average of -$2.9 million and a median of -$2.2 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT plunged 17146.89% in 2022 and soared 94.4% in 2024, its largest moves.
• Over 5 years, EBT stood at -$5.6 million in 2022, then surged by 81.91% to -$1.0 million in 2023, then slumped by 333.75% to -$4.4 million in 2024, then soared by 86.15% to -$613199.0 in 2025, then sank by 276.12% to -$2.3 million in 2026.
• The last three EBT figures came in at -$2.3 million (Q2 2026), -$2.3 million (Q1 2026), and -$613199.0 (Q4 2025), per Business Quant data.